丹鹿通督片临床前安全性评价及肝毒性机制研究
丹鹿通督片是用于腰椎管狭窄症和腰骶椎间盘突出的中成药,临床有转氨酶升高的不良反应报告。本研究在大鼠中开展急性毒性和6个月慢性毒性试验,并采用转录组分析探索肝毒性机制。结果提示肝为毒性靶器官,轻度肝损伤与CYP1A1和CYP1A2表达上调密切相关。
要点
- 丹鹿通督片大鼠6个月重复给药毒性靶器官为肝脏。
- 6.67 g/kg剂量下部分大鼠出现肝小叶间胆管轻度肥大增生,但可逆。
- 肝损伤机制与CYP1A1和CYP1A2表达上调相关。
核心结论
- 丹鹿通督片的毒性靶器官为肝脏,轻度肝损伤机制与CYP1A1和CYP1A2表达上调密切相关。
研究设计与样本
- 急性毒性试验采用最大可行剂量(MFD),观察给药后14天内死亡率、不良反应、体重和摄食量。
- 6个月慢性毒性试验将SD大鼠按体重随机分为四组,实验组分别给予1.67、3.34和6.67 g/kg/day,对照组给予超纯水10 ml/kg,每日一次。
- 慢性毒性试验每周监测体重和摄食量,并在特定时间点检测血液学和生化指标、体重和器官重量及组织病理学。
- 通过转录组分析进一步探讨丹鹿通督片对肝脏的不良反应机制。
主要发现
- 急性毒性试验和6个月慢性毒性试验中,剂量分别为1.67 g/kg和3.34 g/kg时,未观察到死亡或物质相关毒性。
- 6.67 g/kg剂量下连续口服丹鹿通督片13周和26周后,部分大鼠出现肝小叶间胆管轻度肥大和增生,但上述肝脏改变可逆。
- 转录组测序结果显示丹鹿通督片对大鼠肝脏细胞色素P450酶有显著影响,尤其是CYP1亚型。
临床怎么用
- 临床使用丹鹿通督片时应关注肝功能,尤其需警惕转氨酶(ALT、AST)升高的不良反应。
- 基于动物实验结果,该药肝毒性呈剂量相关且轻度可逆,临床需注意剂量与疗程管理。
局限性
- 本研究为临床前动物实验,结果外推至人体需谨慎。
- 肝毒性机制探索基于大鼠转录组分析,尚未在人体中验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Danlu tongdu tablets (DLTD) is a listed Chinese patent medicine collected in the Pharmacopoeia of the People's Republic of China (version 2020). This prescription has been applied in clinics in China for lumbar spinal stenosis and lumbosacral disc herniations. The wide application of Danlu tongdu in therapy has raised some clinical adverse reactions, such as significant elevation of alanine transaminase (ALT) and aspartate transaminase (AST) in individual patients after use. The present study aimed to investigate the safety of Danlu tongdu and analyze its adverse effects on the liver. The maximum feasible dose (MFD) was used to carry out the acute toxicity tests. Mortality, adverse effects, body weight and food consumption were recorded for up to 14 days post treatment. In the 6-month chronic toxicity test, sprague-dawley rats were randomly divided into four groups according body weight, the experimental groups were administrated to rats at the concentrations of 1.67, 3.34 and 6.67 g/kg/day, whereas the control group was received the ultrapure water (vehicle) only, 10 ml/kg, once a day. The animal's body weight, food consumption was monitored weekly. In addition, their hematological and biochemical parameters, body and organ weights and histopathology, were all measured at specific observation time points. Additionally, we further explored the adverse effects mechanism of Danlu tongdu on the liver through transcriptome analysis. No deaths or substance-relative toxicity were observed in the acute toxicity study or the 6-month chronic toxicity study with doses of 1.67 g/kg and 3.34 g/kg, respectively. We found that mild hypertrophy and hyperplasia of hepatic interlobular bile ducts were detected in some rats with doses of 6.67 g/kg after repeated oral administration of Danlu tongdu for 13 and 26 weeks, but the above changes in liver were reversible. The results of transcriptome sequencing showed that Danlu tongdu had a significant effect on cytochrome P450 enzymes in rat liver, especially cytochrome P450 1 (CYP1) subtype. Therefore, the toxic target organ of Danlu tongdu is the liver and the mechanism of mild liver injury is closely related to the up-regulation of cytochrome P450 1A1 (CYP1A1) and cytochrome P450 1A2 (CYP1A2) expression.
引用
- Zhang H, Yang Y, Guo F, et al. Danlu tongdu tablets: Preclinical safety evaluation and mechanism of hepatotoxicity. Front Pharmacol. 2022. PMID: 36408216. doi:10.3389/fphar.2022.1023379
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。